KT501 targets both CD19 and BCMA, aiming to deplete a broad spectrum of B-cells, including plasma cells that drive autoantibody production. The molecule utilizes a proprietary CD3 masking platform intended to boost therapeutic potency while minimizing the risk of cytokine release, a common complication in immune-based therapies. This approach offers a potential off-the-shelf alternative to more complex cell-based treatments.

The IND clearance relies on data from an ongoing Phase 1a study in Australia, where the drug is being tested on adults with rheumatoid arthritis. Weihao Xu, CEO and founder of Kali Therapeutics, noted that the approval validates the company's ability to decouple potency from toxicity. The program is currently operating under a worldwide exclusive licensing agreement with Sanofi, established in March 2026.